Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.

Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG.

Support Care Cancer. 2013 Jul;21(7):2059-66. doi: 10.1007/s00520-013-1766-y.

2.

A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.

Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR.

Support Care Cancer. 2014 Jul;22(7):1807-14. doi: 10.1007/s00520-014-2158-7.

3.

Falls in persons with chemotherapy-induced peripheral neuropathy.

Tofthagen C, Overcash J, Kip K.

Support Care Cancer. 2012 Mar;20(3):583-9. doi: 10.1007/s00520-011-1127-7.

PMID:
21380613
4.

Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.

Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G.

Acta Oncol. 2015 Apr;54(4):463-9. doi: 10.3109/0284186X.2014.980912.

PMID:
25417732
5.

Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.

Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O.

J Cancer Surviv. 2015 Sep;9(3):512-22. doi: 10.1007/s11764-015-0427-1.

PMID:
25876556
6.

Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.

Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ.

Breast Cancer Res Treat. 2016 Sep;159(2):327-33. doi: 10.1007/s10549-016-3939-0.

PMID:
27510185
7.

Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology..

J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Review.

PMID:
24733808
8.

Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy.

Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, Sagar S, Wong R, Yoo HS.

J Acupunct Meridian Stud. 2012 Aug;5(4):156-65. doi: 10.1016/j.jams.2012.05.003.

9.

Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.

Vasquez S, Guidon M, McHugh E, Lennon O, Grogan L, Breathnach OS.

Ir J Med Sci. 2014 Mar;183(1):53-8. doi: 10.1007/s11845-013-0971-5.

PMID:
23832573
10.

Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.

Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, Takagi T, Taniwaki M.

Anticancer Drugs. 2010 Oct;21(9):877-81. doi: 10.1097/CAD.0b013e32833db89d.

PMID:
20679888
11.

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G; CI-PeriNomS Group..

Ann Oncol. 2014 Jan;25(1):257-64. doi: 10.1093/annonc/mdt409.

12.

A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.

Stubblefield MD, McNeely ML, Alfano CM, Mayer DK.

Cancer. 2012 Apr 15;118(8 Suppl):2250-60. doi: 10.1002/cncr.27463. Review.

13.

Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?

Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E.

Support Care Cancer. 2006 Mar;14(3):223-9.

PMID:
16021477
14.

The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.

Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K.

JAMA Neurol. 2016 Jul 1;73(7):860-6. doi: 10.1001/jamaneurol.2016.0383.

PMID:
27183099
15.

Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.

Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S.

J Pain. 2009 Nov;10(11):1146-50. doi: 10.1016/j.jpain.2009.04.006.

16.
17.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group., Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004.

PMID:
23668917
18.

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.

Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, Lunet N.

Support Care Cancer. 2016 Apr;24(4):1571-81. doi: 10.1007/s00520-015-2935-y.

PMID:
26384827
19.

Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy.

Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ.

J Clin Oncol. 2016 Mar 1;34(7):677-83. doi: 10.1200/JCO.2015.62.1276.

20.

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH.

Support Care Cancer. 2009 Aug;17(8):1071-80. doi: 10.1007/s00520-008-0550-x.

PMID:
19089463
Items per page

Supplemental Content

Support Center